Insider · CIK 0001681782

Hagen Brett R

Reports to the SEC for 2 companies · BERKELEY HEIGHTS, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001681782

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-20	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−1,915 sh	$6.72	−$12.9K	0
2026-03-19	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Accounting Officer	AAward	+60.8K sh	—	—	60,800
2025-04-10	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Accounting Officer	AAward	+50.3K sh	—	—	50,262
2025-03-26	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−907 sh	$8.97	−$8,135.155	1,925
2025-02-21	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−96 sh	$10.08	−$967.277	2,832
2025-01-23	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−32 sh	$9.45	−$302.522	2,932
2025-01-23	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−4 sh	$9.94	−$39.761	2,928
2025-01-10	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−332 sh	$0.44	−$146.113	68,174
2024-11-19	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−554 sh	$0.55	−$303.869	68,506
2024-11-05	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−1,655 sh	$0.86	−$1,431.41	69,060
2024-10-22	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−486 sh	$0.77	−$373.151	70,715
2024-10-21	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−479 sh	$0.78	−$373.141	71,201
2024-10-03	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−301 sh	$0.81	−$245.255	71,680
2024-08-19	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−544 sh	$0.76	−$413.168	71,981
2024-08-05	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−1,692 sh	$0.73	−$1,243.282	72,525
2024-07-22	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−481 sh	$0.74	−$355.555	74,217
2024-07-19	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−479 sh	$0.75	−$359.298	74,698
2024-07-02	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−304 sh	$0.72	−$218.88	75,177
2024-05-17	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−541 sh	$0.75	−$405.371	75,481
2024-05-03	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−1,597 sh	$0.80	−$1,271.212	76,022
2024-04-22	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−480 sh	$0.75	−$360	77,619
2024-04-19	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−473 sh	$0.75	−$355.034	78,099
2024-04-02	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−281 sh	$0.77	−$216.932	78,572
2024-02-20	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−494 sh	$0.70	−$343.429	78,853
2024-02-08	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−11.2K sh	$0.67	−$7,493.915	79,347
2024-02-05	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−5,792 sh	$0.67	−$3,880.64	90,497
2024-01-23	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−901 sh	$0.67	−$604.391	96,289
2024-01-04	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−310 sh	$0.64	−$198.09	97,190
2023-12-27	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−28.3K sh	$0.74	−$20.8K	97,500
2023-11-17	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−403 sh	$1.63	−$657.333	125,835
2023-10-20	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−357 sh	$1.54	−$550.137	126,238
2023-10-19	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−358 sh	$1.58	−$565.64	126,595
2023-10-03	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−222 sh	$1.98	−$438.739	126,953
2023-08-17	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−1,653 sh	$2.50	−$4,125.062	127,175
2023-07-20	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−342 sh	$3.35	−$1,144.811	128,828
2023-07-19	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−342 sh	$3.56	−$1,218.033	129,170
2023-06-09	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−5,045 sh	$5.64	−$28.5K	129,512
2023-04-20	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−349 sh	$3.63	−$1,265.3	134,557
2023-04-19	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−348 sh	$3.71	−$1,290.628	134,906
2023-02-02	KLRSKalaris Therapeutics, Inc.A Award	Chief Accounting Officer	AAward	+61.3K sh	—	—	135,254
2023-02-02	KLRSKalaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Accounting Officer	AAward	+114K sh	—	—	251,708
2023-01-20	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−338 sh	$5.14	−$1,738.604	74,004
2023-01-19	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−1,557 sh	$5.08	−$7,905.979	74,342
2022-11-11	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−18K sh	$8.18	−$147K	75,899
2022-11-10	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−5,989 sh	$8.00	−$47.9K	93,910
2022-10-24	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−2,000 sh	$8.13	−$16.3K	99,899
2022-10-21	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−11.3K sh	$8.45	−$95.8K	101,899
2022-10-20	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−345 sh	$9.36	−$3,229.442	113,233
2022-10-19	KLRSKalaris Therapeutics, Inc.S Sale	Chief Accounting Officer	SSale	−345 sh	$9.36	−$3,229.442	113,233
2022-08-16	KLRSKalaris Therapeutics, Inc.A Award	Chief Accounting Officer	AAward	+20K sh	—	—	113,578

Recent filings

Accepted (ET)
Mar 234
Hagen Brett R0001193125-26-119707
SEC(opens sec.gov)
Apr 114
Hagen Brett R0000950170-25-053382
SEC(opens sec.gov)
Mar 274
Hagen Brett R0000950170-25-046263
SEC(opens sec.gov)
Feb 244
Hagen Brett R0000950170-25-025633
SEC(opens sec.gov)
Jan 274
Hagen Brett R0000950170-25-009204
SEC(opens sec.gov)
Jan 134
Hagen Brett R0000950170-25-004833
SEC(opens sec.gov)
Nov 204
Hagen Brett R0000950170-24-129263
SEC(opens sec.gov)
Nov 64
Hagen Brett R0000950170-24-122334
SEC(opens sec.gov)
Oct 234
Hagen Brett R0000950170-24-116646
SEC(opens sec.gov)
Oct 44
Hagen Brett R0000950170-24-112911
SEC(opens sec.gov)
Aug 204
Hagen Brett R0000950170-24-099104
SEC(opens sec.gov)
Aug 74
Hagen Brett R0000950170-24-092806
SEC(opens sec.gov)
Jul 234
Hagen Brett R0000950170-24-085670
SEC(opens sec.gov)
Jul 34
Hagen Brett R0000950170-24-081515
SEC(opens sec.gov)
May 214
Hagen Brett R0000950170-24-062983
SEC(opens sec.gov)
May 74
Hagen Brett R0000950170-24-054510
SEC(opens sec.gov)

Companies

Address

C/O KALARIS THERAPEUTICS, INC. 400 CONNELL DRIVE, SUITE 5500

BERKELEY HEIGHTS, NJ, 07922